# Fentanyl Canonical: https://abierto.us/opportunities/spe2d226r0019 - Solicitation number: SPE2D2-26-R-0019 - Notice type: Presolicitation - Status: No response deadline - Department: Department of Defense - Agency: Defense Logistics Agency - Contracting office: DLA Troop Support (SPE2D2) - NAICS: 325412 Pharmaceutical Preparation Manufacturing - Product or service code: 6505 Drugs and Biologicals - Who can bid, by location: Anywhere in the US. Location does not limit who can bid: a product shipped to the buyer, research at the performer's facility, or work at the contractor's site. A state shown is the delivery point. - First posted: November 4, 2026 - Last posted: November 4, 2026 - SAM.gov: https://sam.gov/workspace/contract/opp/eec0fa45a4254fc3bce148afd4654d06/view ## Description The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Fentanyl Citrate Injection Solution. Procurement details follow. Fentanyl (PF) 50 MCG/ML Injection Solution in 1 ML, 2 ML, 5 ML,10 ML, 20 ML and 50 ML in Vials or Ampules, Pack Size of 1, 2, 5, 10, 20, and 50. Competition will be restricted to domestic sources (vendors providing Active Pharmaceutical Ingredients (API) and Final Dosage Forms (FDF) manufactured domestically), the procurement will be competed among all qualified domestic manufacturers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of War (DoW), Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov/. Interested parties should contact Nancy Fernandez at (445) 737-0731 or Nancy.Fernandedz@dla.mil with any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is November/December of 2026. DLA reserves the right to issue the solicitation before or after the projected solicitation date. ## Open now in the same industry 11 open in NAICS 325412. - Methylphenidate ER (SPE2D226R0013), due November 6, 2026 at 3:00 PM EST. https://abierto.us/opportunities/spe2d226r0013 - FY27 Lenalidomide BPA (36C26227Q0083), due November 12, 2026 at 1:00 PM EST. https://abierto.us/opportunities/36c26227q0083 - Request for Information (RFI) - Specialty Pharmacy – Pharmaceutical Prime Vendor (PPV) 2028 (36E79727Q0001), due November 16, 2026 at 12:00 PM EST. https://abierto.us/opportunities/36e79727q0001 ## Publications - November 4, 2026: Presolicitation. Notice eec0fa45a4254fc3bce148afd4654d06. https://sam.gov/workspace/contract/opp/eec0fa45a4254fc3bce148afd4654d06/view ## Points of contact - Nancy Fernandez, nancy.fernandez@dla.mil, 445-737-0713 - Jason Wray, Jason.wray@dla.mil, 445-737-6304 --- Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/spe2d226r0019.